Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
about
Clinical outcomes in psoriatic arthritis: A systematic literature reviewSwitching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment.Factor XI deficiency diagnosed following use of adalimumab.Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature.Nail psoriasis and biologics.Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective studyAdalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.Adalimumab in dermatologyHome versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study).An evolution in switching therapy for psoriasis patients who fail to meet treatment goals.Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature.Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines.Psoriasis and its treatment with adalimumab.Ustekinumab in clinical practice: response depends on dose and previous treatment.Application of the dermatology life quality index in clinical trials of biologics for psoriasis.Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis.Adalimumab for treating childhood plaque psoriasis: a clinical trial evaluation.Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature.Psoriatic arthritis that responded dramatically when infliximab was switched to adalimumab.Weight-Based Adaptation of TNF-Antagonist Induction versus Maintenance DoseAdalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre.Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients.Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting.Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study.'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network.Comparing the impact of psoriasis and atopic dermatitis on quality of life: co-calibration of the PSORIQoL and QoLIAD.Switching of biologics in psoriasis: Reasons and results.German S3-guidelines on the treatment of psoriasis vulgaris (short version).Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project.S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update.Is weekly dose of adalimumab a simple approach for resistant psoriasis?Long-term efficacy of adalimumab in generalized pustular psoriasis.Adalimumab for the treatment of severe psoriasis and psoriatic arthritis
P2860
Q26995307-F844E42A-4450-4BA5-91F7-78EE98740036Q30612910-BCE8B6DB-BA64-4147-A37F-5276A90946C2Q34190076-FB96109E-760F-420D-A1A1-535DDA785C93Q34247696-D8B97D7E-2B5F-4E1D-8A73-74AF54E54010Q34620323-C8E4FFA8-C904-4334-84FC-1534B615222FQ34965370-0CC7295C-2645-45BF-A874-1A9EDCDDBCFEQ35977689-2D10741C-5614-4A31-860E-8FC90B889DF2Q36521206-1CEEFA84-36B6-474E-A588-F4E08E5DE0D9Q37142425-B958EF29-72A3-4361-8C9C-52FEDDA82F5BQ37184480-BD574A49-9212-4C67-9658-7E534489F321Q37295966-9EDF0EB9-593E-47BE-B822-9CED51F8A345Q37303223-13EE3F45-C928-4AB6-97D1-D14E36AF334BQ37660470-5774D8CB-882D-49B8-984F-DFFC74349F6DQ37676220-D6496DE2-B3F0-45EE-8F62-BD9C23CBDF4DQ37955295-73D6037F-3108-4AB3-84EC-529BE04BD51DQ37998917-C2AEAF8B-5FF9-4A90-9574-BFD19C82DBD0Q38053455-B37AD2CA-F886-451D-BD93-E5E84F267B47Q38127746-549DFAC6-9CA1-4677-9DDC-B2A06BAB7188Q38614496-C59C9687-A29A-4C0C-8647-BE7BA95242B5Q38978414-7CA9B5BE-E685-4506-A35B-6A82D43BF2A0Q42086031-EEB073CB-FE22-4702-A0EC-38A97825FB2AQ42783164-42F6D884-6A8E-44DA-A50C-D06515084040Q44920372-E7D5F609-1CC4-4E05-BB43-262B2DEA0EABQ46007579-50BC9249-AF86-4247-AC29-7CF8D5A33CD2Q46735206-F0ADB8D0-7D79-4DE7-A25F-D00ED596C8DCQ47873720-B6A63319-672A-40D2-80C2-9F21ACFC2B7DQ48077127-017AD559-79B7-444D-9BEC-90B4B2369FD5Q48087641-2C78FDD9-B29F-4A55-8BE9-6C464F007155Q48166630-8C4284B5-63A6-46A8-9069-7CF0915299EDQ48480123-E2508C5C-9DE0-4F92-A2E1-506AD30178BDQ48624250-8956269D-B50D-42CF-8371-CB5CCA2ACB9AQ51753166-A3D2CD71-2FF5-43E9-89E1-0DD6A4A63B5EQ52888818-62EF8D66-FEFD-4883-85BA-0D0B9EF6A29FQ53730255-D439AE36-4FF9-4844-A270-E11BB0091FA4Q55050105-FBDF13EF-226E-4231-B138-00621E5D3B2FQ58434950-2AE20BC4-26C8-490F-8BD2-B695D0E615A3
P2860
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Adalimumab for severe psoriasi ...... treated with other biologics.
@en
Adalimumab for severe psoriasi ...... treated with other biologics.
@nl
type
label
Adalimumab for severe psoriasi ...... treated with other biologics.
@en
Adalimumab for severe psoriasi ...... treated with other biologics.
@nl
prefLabel
Adalimumab for severe psoriasi ...... treated with other biologics.
@en
Adalimumab for severe psoriasi ...... treated with other biologics.
@nl
P2093
P1476
Adalimumab for severe psoriasi ...... treated with other biologics.
@en
P2093
Alessandro Giunta
Arianna Zangrilli
Luca Bianchi
Maria-Sole Chimenti
Marina Papoutsaki
Sergio Chimenti
P304
P356
10.1016/J.JAAD.2006.12.003
P407
P577
2007-06-18T00:00:00Z